Resistance to BRAF-targeted therapy in melanoma
Top Cited Papers
- 1 April 2013
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 49 (6), 1297-1304
- https://doi.org/10.1016/j.ejca.2012.11.019
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNature, 2012
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002